Clinical Trials - October 3, 2014
Kancera gives update on ROR project
Preliminary results from an initial efficacy study show that molecule inhibitor KAN0439834 reduced the number of ROR-expressing leukemia cells. Kancera has completed an initial efficacy study of KAN0439834 (a small molecule inhibitor of ROR1) in an animal model of chronic lymphocytic leukemia. Preliminary results show that KAN0439834 reduces the number of ROR-expressing leukemia cells after 7 days of treatment […]
Uncategorized - October 3, 2014
SciLifeLab launches new facilities
The national board of SciLifeLab has decided to launch nine new national facilities available for Swedish researchers with start January 1st 2015. The new national facilities will be incorporated into the existing SciLifeLab national platforms and include activities also at Umeå University (cryo EM), Linköping University (CyTOF) and Chalmers University of Technology (Big Data). Two facilities […]
Acquisition - October 2, 2014
Cadila Pharmaceuticals buys BioChromix NewCo
Cadila Pharmaceuticals Sweden AB has announced the acquisition of Swedish BioChromix NewCo. BioChromix NewCo was founded in 2013, based the technology previously developed by BioChromix AB and BioChromix Pharma AB, to explore a class of conjugated heteocyclic compounds for the treatment of protein misfolding. Cadila Pharmaceuticals will continue to develop the preclinical and clinical development […]
Collaboration - October 1, 2014
Aerocrine collaborates with Microsoft
The aim is to test secure, cloud-based remote medical device monitoring. Through the collaboration Aerocrine will utilize Microsoft’s cloud services to transmit device telemetry data from physician and company sites in Sweden, UK and US back to Aerocrine for analyses. “The ability to collect vital telemetry data from deployed devices has been a key objective of […]
Collaboration - October 1, 2014
DanDrit Biotech signs new agreement
DanDrit Biotech A/S has signed a contract of collaboration with the University Hospital IRCCS “San Martino”. The collaboration relates to a Phase III adjuvant study of DanDrit’s vaccine in patients with no evidence of disease (“NED”) stage IV colorectal cancer (“CRC”). The primary goal of the study is to evaluate the efficacy of DanDrit’s MelCancerVac (“MCV”) […]
In a new job - September 30, 2014
Karolinska Development CEO leaves post
Karolinska Development has announced that CEO Torbjörn Bjerke leaves the company. Bjerke will be replaced by Klaus Wilgenbus until a new permanent CEO has been appointed. Torbjörn Bjerke leaves his position as CEO on September 30, 2014, and Klaus Wilgenbus steps down from his Board position in Karolinska Development and assumes his new duties with immediate effect. Karolinska Development states […]
